A detailed history of Bridgeway Capital Management, LLC transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Bridgeway Capital Management, LLC holds 127,300 shares of CRVS stock, worth $611,040. This represents 0.02% of its overall portfolio holdings.

Number of Shares
127,300
Previous 127,300 -0.0%
Holding current value
$611,040
Previous $231,000 190.91%
% of portfolio
0.02%
Previous 0.01%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$1.36 - $2.29 $131,920 - $222,130
-97,000 Reduced 43.25%
127,300 $231,000
Q1 2024

May 15, 2024

BUY
$1.76 - $2.41 $132,000 - $180,750
75,000 Added 50.23%
224,300 $399,000
Q3 2023

Nov 14, 2023

BUY
$1.41 - $2.97 $56,400 - $118,800
40,000 Added 36.6%
149,300 $217,000
Q2 2023

Aug 14, 2023

SELL
$1.0 - $3.86 $50,000 - $193,000
-50,000 Reduced 31.39%
109,300 $250,000
Q1 2022

May 16, 2022

SELL
$1.46 - $2.48 $94,900 - $161,200
-65,000 Reduced 28.98%
159,300 $261,000
Q4 2021

Feb 14, 2022

BUY
$2.34 - $5.31 $152,100 - $345,150
65,000 Added 40.8%
224,300 $541,000
Q3 2021

Nov 15, 2021

SELL
$1.89 - $8.53 $94,500 - $426,499
-50,000 Reduced 23.89%
159,300 $771,000
Q2 2021

Aug 16, 2021

BUY
$2.46 - $3.14 $12,300 - $15,700
5,000 Added 2.45%
209,300 $559,000
Q1 2021

May 17, 2021

BUY
$2.86 - $4.77 $201,916 - $336,761
70,600 Added 52.8%
204,300 $629,000
Q4 2019

Feb 14, 2020

BUY
$2.56 - $5.44 $342,272 - $727,328
133,700 New
133,700 $727,000
Q2 2019

Aug 14, 2019

SELL
$3.3 - $4.58 $293,700 - $407,620
-89,000 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$3.75 - $4.97 $35,250 - $46,718
9,400 Added 11.81%
89,000 $358,000
Q4 2018

Feb 14, 2019

SELL
$3.29 - $8.94 $82,250 - $223,500
-25,000 Reduced 23.9%
79,600 $292,000
Q3 2018

Nov 13, 2018

BUY
$8.58 - $11.4 $168,168 - $223,440
19,600 Added 23.06%
104,600 $897,000
Q3 2017

Nov 14, 2017

BUY
$11.3 - $17.23 $960,500 - $1.46 Million
85,000
85,000 $1.36 Million

Others Institutions Holding CRVS

About Corvus Pharmaceuticals, Inc.


  • Ticker CRVS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,553,500
  • Market Cap $223M
  • Description
  • Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...
More about CRVS
Track This Portfolio

Track Bridgeway Capital Management, LLC Portfolio

Follow Bridgeway Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bridgeway Capital Management, LLC with notifications on news.